{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:11:19Z","timestamp":1790295079565,"version":"4.1.0"},"reference-count":48,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2021,1,7]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the risk of neuropsychiatric adverse effects (ie, depression, anxiety, insomnia, dizziness, suicidal behaviour) among patients treated with rilpivirine, dolutegravir and dolutegravir\/rilpivirine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This is a systematic review and meta-analysis of randomised controlled trials. Quality of evidence was assessed using Jadad scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Three electronic databases were searched for available publications up to 1 May 2020. Searches included relevant studies, trial registers, conference proceeding abstracts and grey literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Inclusion criteria<\/jats:title>\n                    <jats:p>Randomised controlled trials with data focused on adult participants (ie, 18 years of age or older) receiving dolutegravir 50\u2009mg, rilpivirine 25\u2009mg or combination of dolutegravir 50\u2009mg\/rilpivirine 25\u2009mg once daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty studies with a minimum duration of 48 weeks and average Jadad score of 4 were included (n=10\u2009998). Primary objective demonstrated a relative risk (RR) synergistic effect on depressive symptoms for dolutegravir\/rilpivirine (RR=2.82; 95% CI (1.12 to 7.10)) when compared with dolutegravir (RR=1.10; 95% CI (0.88 to 1.38)) and rilpivirine (RR=1.08; 95% CI (0.80 to 1.48)). Secondary objectives showed no difference between dolutegravir, rilpivirine and dolutegravir\/rilpivirine to efavirenz. Additionally, excluding efavirenz studies, dolutegravir and dolutegravir\/rilpivirine yielded increased depression (RR=1.34; 95% CI (1.04 to 1.74)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of dolutegravir\/rilpivirine appears to increase the risk of depressive symptoms. Despite the increase, the clinical significance is unknown and needs further study. Additionally, neurotoxicity risk appears similar between dolutegravir, rilpivirine and dolutegravir\/rilpivirine antiretroviral therapy when compared with efavirenz-based antiretroviral therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/sextrans-2020-054821","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T13:27:57Z","timestamp":1617024477000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir\/rilpivirine: a meta-analysis"],"prefix":"10.1136","volume":"97","clinical-trial-number":[{"clinical-trial-number":"nct00543725","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01709084","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01709084","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00540449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00540449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00543725","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00543725","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01263015","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02607956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02607956","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02227238","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02227238","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03110380","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03110380","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02607930","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02607930","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03518060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03518060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04019873","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04019873","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1739-948X","authenticated-orcid":false,"given":"Anthony","family":"Allen Reeves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F","family":"Mosley II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"2024092104001712000_97.4.261.1","unstructured":"Global HIV & AIDS statistics - 2020 fact sheet. UNAIDS (2020). Available: https:\/\/www.unaids.org\/en\/resources\/fact-sheet [Accessed 30 Jul 2020]."},{"key":"2024092104001712000_97.4.261.2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003361"},{"key":"2024092104001712000_97.4.261.3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jad.2019.07.081","article-title":"Clinical correlates of depression chronicity among people living with HIV: what is the role of suicidal ideation?","volume":"258","author":"Tyree","year":"2019","journal-title":"J Affect Disord"},{"key":"2024092104001712000_97.4.261.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0440-y"},{"key":"2024092104001712000_97.4.261.5","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf [Accessed 1 Aug 2020]."},{"key":"2024092104001712000_97.4.261.6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11481-020-09904-z","article-title":"Effect of dolutegravir and sertraline on the blood brain barrier (BBB)","volume":"15","author":"Ma","year":"2020","journal-title":"J Neuroimmune Pharmacol"},{"key":"2024092104001712000_97.4.261.7","unstructured":"Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare 2020."},{"key":"2024092104001712000_97.4.261.8","unstructured":"Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Therapeutics 2019."},{"key":"2024092104001712000_97.4.261.9","unstructured":"Juluca (dolutegravir\/rilpivirine) [prescribing information]. Research Triangle Park, NJ: ViiV Healthcare 2019."},{"key":"2024092104001712000_97.4.261.10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/1570162X12666140128121900","article-title":"Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in echo and thrive","volume":"11","author":"Ryan","year":"2013","journal-title":"Curr HIV Res"},{"key":"2024092104001712000_97.4.261.11","unstructured":"HIV\/AIDS Glossary Backbone Definition . National Institutes of health, 2020. Available: https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/glossary\/4595\/backbone [Accessed 16 Apr 2020]."},{"key":"2024092104001712000_97.4.261.12","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2024092104001712000_97.4.261.13","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/jac\/dky298","article-title":"High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600\u2009mg daily","volume":"73","author":"Seden","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024092104001712000_97.4.261.14","unstructured":"Sustiva (efavirenz) [prescribing information]. Princeton, NJ: Bristol Myers Squibb 2019."},{"key":"2024092104001712000_97.4.261.15","unstructured":"Nordic Cochrane Centre . Review manager 5 (RevMan 5). version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"2024092104001712000_97.4.261.16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/09540121.2015.1096890","article-title":"Patient-Reported outcomes in the single-tablet regimen (StAR) trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment","volume":"28","author":"Wilkins","year":"2016","journal-title":"AIDS Care"},{"key":"2024092104001712000_97.4.261.17","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9080195","article-title":"Improved central nervous system symptoms in people with HIV without objective neuropsychiatric complaints switching from efavirenz to rilpivirine containing cART","volume":"9","author":"Vera","year":"2019","journal-title":"Brain Sci"},{"key":"2024092104001712000_97.4.261.18","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT01709084, a clinical trial comparing the efficacy of tenofovir disoproxil Fumarate\/Emtricitabine\/Rilpivirine (TDF\/FTC\/RPV) versus TDF\/FTC\/Efavirenz (TDF\/FTC\/EFV) in patients with undetectable plasma HIV-1 RNA on current first-line treatment (SALIF); 2012 October 17. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01709084?term=rilpivirine&rslt=With&draw=2&rank=4 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.19","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT00540449, a clinical trial in treatment naive HIV-1 patients comparing TMC278 to efavirenz in combination with tenofovir + emtricitabine. (echo); 2007 October 8. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00540449?term=rilpivirine&rslt=With&draw=1 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.20","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT00543725, TMC278-TiDP6-C215: a clinical trial in treatment naive HIV-subjects patients comparing TMC278 to efavirenz in combination with 2 nucleoside\/nucleotide reverse transcriptase inhibitors (thrive); 2007 October 15. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00543725 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283612419"},{"key":"2024092104001712000_97.4.261.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"2024092104001712000_97.4.261.23","unstructured":"A Trial Comparing GSK1349572 50mg Plus Abacavir\/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) - Full Text View. Full Text View - ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01263015 [Accessed 27 Dec 2020]."},{"key":"2024092104001712000_97.4.261.24","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-Daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (flamingo): 96 week results from a randomised, open-label, phase 3B study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"2024092104001712000_97.4.261.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"2024092104001712000_97.4.261.26","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"Fixed-Dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3B study","volume":"4","author":"Orrell","year":"2017","journal-title":"Lancet HIV"},{"key":"2024092104001712000_97.4.261.27","first-page":"549","article-title":"International study of patients with HIV on rifampicin ING Study Group. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, Noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024092104001712000_97.4.261.28","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"2024092104001712000_97.4.261.29","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT02607956, safety and efficacy of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide versus dolutegravir + Emtricitabine\/Tenofovir Alafenamide in HIV-1 infected, antiretroviral treatment-naive adults; 2015 November 18. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02607956?term=dolutegravir&rslt=With&type=Intr&age=12&draw=2&rank=18 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.30","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3166"},{"key":"2024092104001712000_97.4.261.31","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT02227238; comparative efficacy and safety study of dolutegravir and Lopinavir\/Ritonavir in second-line treatment; 2014 August 28. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02227238 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.32","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT03110380; switching to a fixed dose combination of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) in HIV-1 infected adults who are virologically suppressed; 2017 April 12. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03110380 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.33","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2024092104001712000_97.4.261.34","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National library of medicine (US). 2000 Feb 29 -. identifier NCT02607930; safety and efficacy of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide versus Abacavir\/Dolutegravir\/Lamivudine in HIV-1 infected, antiretroviral treatment-na\u00efve adults; 2015 November 18. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02607930 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"2024092104001712000_97.4.261.36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu477"},{"key":"2024092104001712000_97.4.261.37","doi-asserted-by":"crossref","unstructured":"Thibaut G , Val\u00e9rie F , Anne-Marie T . Dolutegravir cerebrospinal fluid diffusion in HIV-1\u2013Infected patients with central nervous system impairment. Open Forum Infectious Diseases 2019;6.","DOI":"10.1093\/ofid\/ofz174"},{"key":"2024092104001712000_97.4.261.38","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1007\/s12035-018-1273-8","article-title":"Nanoformulated antiretroviral therapy attenuates brain metabolic oxidative stress","volume":"56","author":"Montenegro-Burke","year":"2019","journal-title":"Mol Neurobiol"},{"key":"2024092104001712000_97.4.261.39","unstructured":"Yagura H , Watanabe D , Nakauchi T . Effect of dolutegravir plasma concentration on central nervous system side effects. Seattle, Washington: Poster present at: Conference on retroviruses and opportunistic infections, 2017. https:\/\/www.croiconference.org\/abstract\/effect-dolutegravir-plasma-concentration-central-nervous-system-side-effects\/#:~:text=At%20least%20one%20of%20the,anxiety%20%5B3%20(7%25)%5D"},{"key":"2024092104001712000_97.4.261.40","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062174"},{"key":"2024092104001712000_97.4.261.41","first-page":"199","article-title":"Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"Guti\u00e9rrez","year":"2014","journal-title":"AIDS Rev"},{"key":"2024092104001712000_97.4.261.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01421-13"},{"key":"2024092104001712000_97.4.261.43","doi-asserted-by":"crossref","first-page":"e00837","DOI":"10.1128\/AAC.00837-17","article-title":"Mdr1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption","volume":"61","author":"Reznicek","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092104001712000_97.4.261.44","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"2024092104001712000_97.4.261.45","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2"},{"key":"2024092104001712000_97.4.261.46","unstructured":"National Center for Biotechnology Information . PubChem compound summary for Cid 54726191, dolutegravir. Available: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dolutegravir [Accessed 25 Dec 2020]."},{"key":"2024092104001712000_97.4.261.47","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03518060, Dolutegravir\/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1 (JUNGLE); 2018 May 8. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03518060 [Accessed 17 Apr 2020]."},{"key":"2024092104001712000_97.4.261.48","unstructured":"ClinicalTrials.gov [Internet] . Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT04019873, 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor; 2019 July 15. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04019873 [Accessed 17 Apr 2020]."}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2020-054821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:02:09Z","timestamp":1726902129000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2020-054821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,5,17]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/sextrans-2020-054821"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2020-054821","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}